An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients beliefs and attitudes towards the disease. Br J Dermatol. 1996;135:533–537.
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–456.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Balato N, Ayala F, et al. Psoriasis in elderly and non-elderly population. G Ital Dermatol Venereol. 2016;151:587–595.
   PubMed Web of Science ®Google Scholar
• Caruso C, Buffa S, Candore G, et al. Mechanisms of immunosenescence. Immun Ageing. 2009;22:6–10.
   Google Scholar
• Šahmatova L, Sügis E, Šunina M, et al. Signs of innate immune activation and premature immunosenescence in psoriasis patients. Sci Rep. 2017;7:7553.
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology Work Group1, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–174.
   PubMed Web of Science ®Google Scholar
• Thivolet J, Nicolas JF. Skin ageing and immune competence. Br J Dermatol. 1990;122:77–81.
   PubMed Web of Science ®Google Scholar
• Hawk JLM. Photosensitivity in the elderly. Br J Dermatol. 1990;122(Suppl. 35):29–41.
   PubMed Web of Science ®Google Scholar
• Balato N, Patruno C, Napolitano M, et al. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31:233–238.
   PubMed Web of Science ®Google Scholar
• Martin JA, Laube S, Edwards C, et al. Rate of acute adverse events for narrow-band UVB and Psoralen-UVA phototherapy. Photodermatol Photoimmunol Photomed. 2007;23:68–72.
   PubMed Web of Science ®Google Scholar
• Powell JB, Gach JE. Phototherapy in the elderly. Clin Exp Dermatol. 2015;40:605.
   PubMed Web of Science ®Google Scholar
• Koo JYM, Levin E, Leon A, et al. Moderate to severe psoriasis. Fourth. Boca Raton: CRC Press; March 18 2014
   Google Scholar
• Carretero G, Ribera M, Belinchón I, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:598–616.
   PubMedGoogle Scholar
• Borghi A, Corazza M, Bertoldi AM, et al. Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety. Acta Derm Venereol. 2015;95:332–336.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94:293–297.
   PubMed Web of Science ®Google Scholar
• Boffa MJ, Chalmers RJG. Methotrexate for psoriasis. Clin Exp Dermatol. 1996;21:399–408.
   PubMed Web of Science ®Google Scholar
• Fairris GM, Dewhurst AG, White JE, et al. Methotrexate dosage in patients aged over 50 with psoriasis. BMJ. 1989;298:801–802.
   PubMed Web of Science ®Google Scholar
• Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2011;65:537–545.
   PubMed Web of Science ®Google Scholar
• Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95–102.
   PubMed Web of Science ®Google Scholar
• Wong JW, Koo JY. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract. 2012;2012:367475.
   PubMedGoogle Scholar
• Evans WE, Christensens ML. Drug interactions with methotrexate. J Rheumatol Suppl. 1985 Dec;12(Suppl 12):15–20.
   PubMedGoogle Scholar
• Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol. 1995 Nov;34(Suppl 2):20–25.
   PubMedGoogle Scholar
• Maza A, Montaudié H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):19–27.
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996;35:710–719.
   PubMed Web of Science ®Google Scholar
• Campana C, Regazzi MB, Buggia I, et al. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet. 1996;30:141–179.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou S, Assaf M, et al. Impact of renal impairment on the pharmacokinetics of apremilast and metabolite M12. Clin Pharmacol Drug Dev. 2016;5:469–479.
   PubMed Web of Science ®Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris–update 2015–short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–2294.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther. 2016;10:1763–1770.
   PubMed Web of Science ®Google Scholar
• Militello G, Xia A, Stevens SR, et al. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006 Sep;55(3):517–519.
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep;63(3):448–456.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Pavlidis A, Dattola A, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. Expert Opin Drug Saf. 2016;15:1459–1462.
   PubMed Web of Science ®Google Scholar
• Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225:312–319.
   PubMed Web of Science ®Google Scholar
• Garber C, Plotnikova N, Au SC, et al. A biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. J Drugs Dermatol. 2015;14:846–852.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12:225–229.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41:974–980.
   PubMed Web of Science ®Google Scholar
• Momose M, Asahina A, Hayashi M, et al. Biologic treatments for elderly patients with psoriasis. J Dermatol. 2017;44:1020–1023.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41:564–566.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60–69.
   PubMed Web of Science ®Google Scholar
• Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35:135–144.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273–286.
   PubMed Web of Science ®Google Scholar